Related Experiment Video
Updated: Aug 31, 2025
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Mepolizumab-Induced Posterior Reversible Encephalopathy Syndrome (PRES), a new patient report
Vikram V Puram1, Dana Ghazaleh2, Apameh Salari3
1University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA.
Background:
Posterior Reversible Encephalopathy Syndrome (PRES) is a neurotoxic state characterized by seizures, headache, vision change, paresis, and altered mental status. PRES has an important place in medicine due to the wide variety of causative diseases, infections, and medications that precipitate its mysterious onset. Although exposure to medications, particularly immunosuppressants, cancer chemotherapy, and biologic drugs, is a common occurrence in patients who develop PRES, Mepolizumab has never before been associated.
Case Presentation:
This report of a 67-year-old male patient outlines the first reported case of Mepolizumab-induced PRES in the literature.
Conclusions:
Treatment of severe asthma, asthma-exacerbations, and diseases such as eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) with Mepolizumab is rapidly gaining popularity ever since the drug's recent FDA-approval. This report aims to raise awareness of this potentially life-threatening and previously unreported side effect of Mepolizumab since early identification of the causative agent is the key to preventing the severe neurologic disability and possible death that may occur from the delayed treatment of PRES.
